Archives for November 22, 2010

← 2010

Dispatches from the CIAA Congress

Science needed to plug trust gap between traditional use and opinions

By Jess Halliday in Brussels

EFSA does not believe that a negative opinion is the end of the road for 13.1 health claims, but it expects some to be resubmitted with a new slate of data behind them, according to Catherine Geslain-Lanéelle.

Cran-Max boosts PAC content to 7.2 percent

By Stephen Daniells

US firm Proprietary Nutritionals Inc (PNI) has announced that its Cran-Max ingredient is now available with a minimal PAC (proanthocyanidin) content of 7.2 percent per 500 mg.

Dispatches from HIE 2010

Martek discusses algal omega-3 opportunities

By Nathan Gray

Martek Bioscience has said it is expanding its omega-3 range by commercializing two new products – a new emulsion version of its vegetarian life’s DHA and a DHA/EPA blend from algal sources.

Folic acid fears for fetus unfounded: Study

By Stephen Daniells

Supplements containing folic acid, a key recommendation for women of child-bearing age, do not produce an accumulation of un-metabolized folic acid in the fetus, says a new study from Germany.

Dispatches from HIE 2010

EFSA CLA rejection stalls business development

By Shane Starling

Lipid Nutrition global group manager in marketing, John Kurstjens, is “a little bit disappointed” about the recent EFSA health claim opinion on CLA which included a range of claim dismissals but remained strangely silent about the claim that matters most...